✦ LIBER ✦

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

✍ Scribed by Dieter Jocham; Axel Richter; Lothar Hoffmann; Klaus Iwig; Dirk Fahlenkamp; Günther Zakrzewski; Eberhard Schmitt; Thomas Dannenberg; Walter Lehmacher; Jörn von Wietersheim; Christian Doehn

Book ID: 117285660
Publisher: The Lancet
Year: 2004
Tongue: English
Weight: 103 KB
Volume: 363
Category: Article
ISSN: 0140-6736
DOI: 10.1016/s0140-6736(04)15590-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Autologous tumour cell vaccine may reduc

Autologous tumour cell vaccine may reduce risk of tumour progression in people with primary renal cell carcinoma: Abstracted from: Jocham D, Richter A, Hoffmann L et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004;363:594–599.

✍ Chris Coppin 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 234 KB

Multicenter randomised phase-III trial t

Multicenter randomised phase-III trial to compare tumour nephrectomy plus adjuvant autologous tumour cell-lysate vaccine versus tumour nephrectomy without adjuvant treatment for renal cell carcinoma PT2-3BPN0-3M0

✍ C. Dochn; A. Richter; W. Lehmacher; D. Jocham 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 179 KB

429 Adjuvant vaccination in patients wit

429 Adjuvant vaccination in patients with renal cell carcinoma following radical nephrectomy is effective: Final results of a multicentre phase-III trial

✍ C. Doehn; A. Richter; W. Lehmacher; D. Jocham 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 213 KB

AN ADJUVANT VACCINATION WITH RENIALE® PR

AN ADJUVANT VACCINATION WITH RENIALE® PROLONGS SURVIVAL IN PATIENTS WITH RENAL CELL CARCINOMA FOLLOWING RADICAL NEPHRECTOMY: SECONDARY ANALYSIS OF A MULTICENTRE PHASE-III TRIAL

✍ Doehn, C.; Richter, A.; Theodor, R.A.; Lehmacher, W.; Jocham, D. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 46 KB

An adjuvant autologous therapeutic vacci

An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

✍ Christopher Wood; Pramod Srivastava; Ronald Bukowski; Louis Lacombe; Andrei I Go 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 312 KB

A MULTICENTRE, RANDOMISED, PHASE 3 TRIAL

A MULTICENTRE, RANDOMISED, PHASE 3 TRIAL OF A NOVEL, AUTOLOGOUS, THERAPEUTIC VACCINE (VITESPEN) VS. OBSERVATION AS ADJUVANT THERAPY IN PATIENTS AT HIGH RISK OF RECURRENCE AFTER NEPHRECTOMY FOR RENAL CELL CARCINOMA

✍ P. Mulders; C.G. Wood; S. Gorelov; K. Krajka; S. Mikhailov; A. Gorelov; S.D. Fos 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 73 KB